Viz HDS, Viz Volume Plus, Viz ICH+
Viz.ai, Inc. • Radiology • 02/05/2024
Device Purpose
The Viz HDS system utilizes an artificial intelligence algorithm to automatically process non-contrast CT head scans, providing quantitative analysis of intracranial hyperdensities, lateral ventricles, and midline shift. Its methodology involves segmenting these structures from DICOM images and generating volumetric measurements and visual overlays to aid physicians in assessing single time-point brain scans.
Summary
The Viz HDS, Viz Volume Plus, Viz ICH+ system is a software-only medical image processing tool designed to assist clinicians by automating the analysis of non-contrast CT (NCCT) head scans. It employs a locked artificial intelligence machine learning (AI/ML) algorithm to automatically identify, label, visualize, and quantify key segmentable brain structures, specifically intracranial hyperdensities, lateral ventricles, and midline shift. The software processes DICOM-formatted NCCT scans acquired at a single time point, generating output in DICOM format that is sent to a PACS system. This output includes a summary series with calculated measurements and a segmentation series with RGB overlays on the original images to visually differentiate the segmented regions like hyperdensities and ventricles, and to display the midline shift. The system's output is intended for review by a physician alongside the patient's original images. The detailed output provides volumetric data for intracranial hyperdensities and lateral ventricles (including asymmetry ratio), and measures the distance of midline shift. Clinical performance data demonstrated the system's accuracy compared to ground truth established by radiologists. Mean absolute error for total hyperdensity volume was less than 7.5 mL, for lateral ventricle volumes less than 3 mL each, and for midline shift distance less than 2 mm (all at upper 95% CI). Furthermore, the DICE score, indicating agreement with manual measurements for hyperdensities and lateral ventricles, showed a lower 95% CI bound greater than 70%, meeting predefined performance goals across various stratification factors.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the AI/ML algorithm's performance vary across different CT scanner manufacturers and imaging protocols not included in the stratification data?; What is the processing time for a typical NCCT head scan, and how does this integrate into acute neurological emergency workflows?; Are there plans to expand the algorithm's capabilities to detect or quantify other critical brain pathologies or structures beyond hyperdensities, ventricles, and midline shift?; How robust is the algorithm in the presence of significant imaging artifacts or atypical patient anatomy?; What specific training datasets were used for the AI/ML algorithm, and what measures were taken to ensure diversity and minimize bias in its development and validation?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly